Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Lt4.0
Luteolin – Forschung
Hilft wahrscheinlich
48 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Luteolin scheint in 4 von 4 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2013–2026 mit einer typischen Studiengröße von 185 Teilnehmenden.
Basierend auf 48 Studien · 4 Meta-Analysen · 11 RCTs · 4,308 Teilnehmende insgesamt
InflammationReduzierte systemische und neuronale Entzündung · 2-4 weeks
Überwiegend Mechanismus / Beobachtung24 Studien
Therapeutic & clinical
Hilft wahrscheinlich13 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung9 Studien
Cognitive function
Überwiegend Mechanismus / Beobachtung5 Studien
Immune supportReduzierte allergische Reaktionen und Mastzellaktivität · 2-4 weeks
Überwiegend Mechanismus / Beobachtung4 Studien
Glucose & metabolic
Überwiegend Mechanismus / Beobachtung3 Studien
Heart & blood pressure
Zu wenige bewertete Studien2 Studien
Cholesterol & lipids
Zu wenige bewertete Studien2 Studien
Liver health
Zu wenige bewertete Studien2 Studien
Depression & mood
Zu wenige bewertete Studien1 Studie
Anxiety & stressAnxiolytische Eigenschaften über GABAerge und anti-neuroinflammatorische Signalwege · 2-4 weeks
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 34 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
100%
über Studien hinweg
Untersuchte Personen
4,308
typische Studie: 185 Personen
Stärkste Designs
15
4 gepoolt, 11 randomisiert
Zeigte Nutzen
100%
4/4 Studien
Wie lange Studien liefen
1–3 Monate
1
3+ Monate
3
Untersuchte Populationen
Neurodegenerative disease patients2
Not specified2
Idiopathic pulmonary fibrosis patients1
CNS injury patients1
Aktives Forschungsgebiet
44 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
201320192026
1Systematische ÜbersichtCited 26×n=1,140 · large study2023
The results of a meta-analysis of 12 RCTs indicate that TCM intervention can improve the clinical treatment efficacy of CAG.
Weng J et al. · Annals of medicine (2023)
The results of a meta-analysis of 12 RCTs indicate that TCM intervention can improve the clinical treatment efficacy of CAG.
NPAs identified seven hub TCM and 13 target genes associated with their actions, while bioinformatics analysis identified two DEGs between normal and CAG gastric tissues.
Finally, molecular docking was employed to reveal the mechanism of action of the active molecules in TCM on the DEGs.
2Idiopathic pulmonary fibrosis treatment efficacyMeta-Analysen=896 · large study2024
These results provided scientific basis for the clinical use of Danhong injection for the treatment of IPF, and provided a new direction to explore the potential mechanism of action of Danhong injection.
Wu X et al. · Medicine (2024)
These results provided scientific basis for the clinical use of Danhong injection for the treatment of IPF, and provided a new direction to explore the potential mechanism of action of Danhong injection.
3Neuroprotection in brain and spinal cord injurySystematische ÜbersichtCited 13×2025
Faysal M et al. · Naunyn-Schmiedeberg's archives of pharmacology (2025)
Flavonoids can enhance injury healing, reduce lesion size, and enhance synaptic plasticity and neurogenesis.
The full potential of flavonoids lies in their bioavailability, dose, and administration methods, but there are still challenges to overcome.
This review explores flavonoid-induced neuroprotection, its clinical implications, future research opportunities, and molecular mechanisms, highlighting the potential for innovative CNS injury therapies and improved patient health outcomes.
The utilization of natural products holds significant promise for the prevention and treatment of neurodegenerative diseases (ND).
The review provides evidence that natural products and their bioactive compounds could be beneficial in the treatment of neurodegenerative disorders.
This article delineates the Keap1-Nrf2-ARE pathway's role in ND progression, shedding light on the therapeutic efficacy of natural products and their bioactive constituents that have demonstrated neuroprotective properties.
The primary focus of this systematic review is to analyze the current state of the literature regarding treating liver ailments using extracts from medicinal plants, examining their phytochemical composition, and addressing associated safety considerations.
Gonfa YH et al. · Zeitschrift fur Naturforschung. C, Journal of biosciences (2025)
The application of natural products derived from medicinal plants in treating liver injuries is rooted in their efficacy, cost-effectiveness, and safety profile, contributing to their popularity.
Many studies, encompassing in vitro, in vivo, preclinical, and clinical investigations, have demonstrated that the extracts of medicinal plants mitigate chemical-induced liver damage using animal models.
However, intensive research efforts regarding the safety, regulatory standard, and quality control issues for using medicinal plants as hepatoprotective agents remain the strong task of scholars.
Both natural and synthetic NRF2 activators mitigate toxic lipid accumulation and oxidative injury, supporting NRF2 modulation as a promising strategy for preventing and treating lipid metabolic disorders such as NAFLD, atherosclerosis, and metabolic syndrome.
Arif Asghar M et al. · Journal of biochemical and molecular toxicology (2025)
Groß Nutzen
← SchlechterKein EffektBesser →
Clinical meta-analysis demonstrated that NRF2 activators reduced toxic lipid parameters, including triglycerides (↓ 21.81%), LDL (↓ 18.36%), and total cholesterol (↓ 14.15%).
Network pharmacology identified 985 overlapping genes linking NRF2 activation to oxidative stress, lipid peroxidation, and fatty acid metabolism.
Sixteen natural and synthetic NRF2 activators were highlighted, with molecular docking showing strong KEAP1 binding by quercetin (-9.2 kcal/mol) and luteolin (-9.2 kcal/mol), consistent with disruption of KEAP1-NRF2 interactions and detoxification pathway activation.
So the synergistic effects of flavonoids with other drugs, pharmacokinetic studies, clinical trials and the safety of flavonoids are also incorporated in the discussion.
Cao Y et al. · Pharmacological research (2021)
So the synergistic effects of flavonoids with other drugs, pharmacokinetic studies, clinical trials and the safety of flavonoids are also incorporated in the discussion.
It is believed that more breakthrough studies are needed.
Overall, this review may shed some new light on the explicit recognition of the mechanisms of anti-hypertension actions of flavonoids, pointing out the limitations of relevant research at the current stage and the aspects that should be strengthened in future researches.
9Brain fog symptoms improvementSystematische ÜbersichtCited 19×n=17 · very small study2024
Two studies showed that the use of Palmitoylethanolamide and Luteolin (PEA-LUT) improved cognitive impairment.
Gorenshtein A et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2024)
Noninvasive brain stimulation and hyperbaric oxygen therapy showed promising results in the treatment of brain fog symptoms caused by long-COVID, with improved perfusion and cortical excitability.
Furthermore, both rehabilitation strategies and PEA-LUT administration have been associated with improvements in symptoms of brain fog.
Future studies should explore combinations of interventions and include longer follow-up periods to assess the long-term effects of these treatments.
The neuroprotective properties of PEA-LUT appear to enhance recovery from post-COVID olfactory dysfunction.
Shi Y et al. · European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2026)
Of the seven studies, five (71.4%) used the full Threshold-Discrimination-Identification (TDI) scoresystem to assess olfactory function, while two (28.6%) used only the Identification ("I") subscale; 332 patients (63.2%) received PEA-LUT + OT therapy and 203 (38.8%) received OT alone.
Meta-analysis of these studies showed that patients receiving PEA-LUT combined with OT had significantly higher TDI scores compared to those receiving OT alone (Standard mean difference (SMD) = 0.90; 95% CI: 0.24-1.58; P < 0.01).
The overall response rate was also significantly higher in the combination group (Risk difference (RD) = 0.33; 95% CI: 0.01-0.64; P = 0.04).
15Allergic rhinitis and asthma outcomesSystematische Übersicht2026
Mapping natural compounds to specific disease stages provides a molecular basis for precision medicine approaches.
Zhang X et al. · International journal of molecular sciences (2026)
During sensitization, flavonoids (quercetin, luteolin, apigenin, baicalin) and polyphenols (curcumin, resveratrol) target the epithelial-dendritic cell axis by suppressing alarmin release and blocking dendritic cell maturation.
In acute exacerbation, flavonoids (hispidulin, quercetin) and isoquinoline alkaloids (coptisine) exhibit rapid intervention through mast cell stabilization and neurogenic inflammation suppression.
In chronic remodeling, stilbenes (resveratrol) and flavones (baicalin, baicalein) reverse established structural changes through TGF-β1/Smad, PTEN/PI3K/AKT, and PDGF-BB/PDGFR-β pathways.
We also suggest simple ways to address some of the key pathogenetic processes involved in ASD.
Katiraei P et al. · International journal of molecular sciences (2026)
Individuals with ASD have a constellation of neurological, behavioral, sensory, feeding, gastrointestinal, and immunological issues.
Here we discuss how various environmental, pathogenic, and stress factors can disrupt gut-brain homeostasis to create susceptibility and epigenetic effects that contribute to the development of ASD.
We also suggest simple ways to address some of the key pathogenetic processes involved in ASD.
17Neuroinflammation modulation in affective disordersSystematische Übersicht2026
Future research should prioritize bioavailability-enhanced formulations, standardized clinical trials, and biomarker-guided stratification to fully establish the therapeutic potential of flavonoids in affective disorders.
Rosas-Sánchez GU et al. · International journal of molecular sciences (2026)
This narrative review synthesizes current preclinical and clinical evidence on the role of flavonoids and related natural compounds in modulating neuroinflammation and affective disorders.
Preclinical studies consistently demonstrate anxiolytic and antidepressant effects for compounds such as quercetin, luteolin, apigenin, and chrysin; however, clinical evidence remains limited and methodologically heterogeneous.
Future research should prioritize bioavailability-enhanced formulations, standardized clinical trials, and biomarker-guided stratification to fully establish the therapeutic potential of flavonoids in affective disorders.
18Olfactory recoveryRCTCited 76×n=185 · medium study2022
Among individuals with olfactory dysfunction post-COVID-19, combining PEA-LUT with olfactory training resulted in greater recovery of smell than olfactory training alone.
Di Stadio A et al. · Current neuropharmacology (2022)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
The intervention group showed significantly greater improvement in olfactory threshold, discrimination, and identification scores compared to controls (p=0.0001).
Overall, 92% of patients in the intervention group improved versus 42% of controls.
Magnitude of recovery was significantly greater in the intervention group versus control (12.8 + 8.2 versus mean 3.2 + 3), with >10-fold higher prevalence of anosmia in control versus intervention groups at the 90-day endpoint.
Patients receiving treatment with um-PEA-LUT alone demonstrated subclinical improvement (< 3 point odor identification improvement) more often than patients receiving olfactory training with placebo (p < 0.0001.) CONCLUSIONS: Olfactory training plus once daily um-PEA-LUT resulted in greater olfactory recovery than either therapy alone in patients with long-term olfactory function due to COVID-19.
Di Stadio A et al. · European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2023)
202 patients with persistent COVID-19 olfactory dysfunction (>6 months) randomized to olfactory training+placebo, once- or twice-daily um-PEA-LUT alone, or combined once-daily um-PEA-LUT plus olfactory training
At 90 days, odor identification improved >3 points in 89.2% of the combined-therapy group vs 36.8% with olfactory training plus placebo (p < 0.00001)
Combined um-PEA-LUT plus olfactory training outperformed either therapy alone; no adverse events
20Body weight reductionRCTCited 28×n=100 · medium study2023
In conclusion, these results confirm that Altilix® supplementation has a significant effect on cardiometabolic parameters not only in obese subjects but also in pre-obesity subjects.
Terzo S et al. · Nutrients (2023)
After six months of treatment Altilix® significantly reduced body weight, glycemic, and lipid parameters (total cholesterol, triglycerides, LDL-cholesterol) and improved hepatic functionality, CIMT, and FMD.
Fifty subjects from the original study cohort (which consisted of 100 subjects) were chosen with BMI ≥ 25 and < 30 kg/m2.
All subjects received the Altilix® supplement (150 mg/day) or placebo using a computer-based random allocation system.